President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?

Eli Lilly generated roughly $65 billion of revenue in 2025, with Mounjaro and Zepbound sales topping $30 billion and analysts projecting annual obesity-drug market potential of more than $95 billion, with some estimates near $200 billion. The article argues Lilly's manufacturing expansion, pipeline, and market leadership support a premium valuation, though competition and execution risk remain. Overall, the piece is constructive on Lilly's long-term fundamentals but is framed as commentary rather than a near-term catalyst.

Analysis

LLY is still the cleanest way to express the obesity supercycle, but the more interesting trade is that the market is moving from a single-product story to an industrial capacity race. The bottleneck is no longer demand; it is fill-finish, injectable device supply, and the ability to sustain launch velocity across geographies. That shifts value creation toward companies that can convert capex into reliable volume growth, while suppliers with exposure to sterile manufacturing, packaging, and cold-chain logistics should see a multi-quarter tailwind.

The second-order loser is not just NVO; it is any late entrant that needs to spend heavily to catch up while pricing power is still being set by the leaders. If next-generation agents improve convenience or maintenance but not materially better adherence/outcomes, the market may not fragment quickly enough to justify the long-dated development spend at smaller names. That creates a subtle pressure on VKTX and similar programs: the bar keeps rising as LLY’s commercial scale effectively shortens the time window for challengers to monetize.

The main risk is not political noise; it is expectation compression. When a stock already discounts years of above-trend growth, even a modest slowdown in prescription acceleration or a manufacturing hiccup can re-rate the multiple before fundamentals actually deteriorate. Over the next 1-3 quarters, watch for any signal that refill rates, payer pushback, or adverse-event headlines force a slower cadence of sequential beats; that would hit the stock harder than a headline about competition.

Consensus appears to be underestimating how much of the obesity market will remain concentrated if supply remains the key constraint. In that setup, the winner is not necessarily the best molecule, but the best scaled distribution machine. That favors LLY on a relative basis, but it also makes the upside more path-dependent than most bull cases admit: the stock works best if execution keeps surprising to the upside, not merely meeting already-robust numbers.

Key Decisions for Investors

• Maintain a tactical long LLY, but prefer call spreads over outright stock for the next 3-6 months to capture upside while capping valuation risk; best risk/reward is on pullbacks after any supply or sentiment-driven air pockets.
• Pair trade: long LLY / short NVO for 1-2 quarters to express relative execution and manufacturing advantages; thesis breaks if NVO meaningfully narrows supply gaps or gains faster payer traction.
• Add a basket long of obesity supply-chain enablers on weakness — contract manufacturing, sterile packaging, and cold-chain beneficiaries — to diversify away from single-name valuation risk.
• Avoid initiating fresh longs in VKTX/early-stage obesity developers ahead of readouts unless size is small and options-defined; the probability-adjusted payoff worsens as the commercial leaders continue to expand scale.
• If LLY gaps higher on any demand headline, fade part of the move with a short-dated covered-call overwrite; implied vol should stay rich given the stock’s sensitivity to execution surprises.